Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAA2 | P54646 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | TNKS | O95271 | 1/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | MERTK | Q12866 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9301750 | 0.79 | TNKS (0.45) | PRKAA2TNKSTNKS2PARP2PTGS1 | |
| SCHEMBL9300806 | 0.75 | PTGS1 (0.36) | PRKAA2ALDH1A1KMT2APTGS1PTGS2 | |
| SCHEMBL9302519 | 0.72 | ADORA2A (0.43) | ADORA2ATNKSTNKS2PARP2ALDH1A1 | |
| SCHEMBL8900960 | 0.70 | MAPT (0.42) | PRKAA2ADORA2AALDH1A1HPGDKMT2A | |
| SCHEMBL3707071 | 0.70 | GRM2 (0.53) | PRKAA2ADORA2ARXRATNKSTNKS2 | |
| SCHEMBL753198 | 0.68 | PRKAA2 (0.64) | PRKAA2ADORA2ARXRAALDH1A1KMT2A | |
| SCHEMBL14114892 | 0.68 | PRKAA2 (0.68) | PRKAA2ADORA2ARXRATNKSTNKS2 | |
| SCHEMBL526202 | 0.68 | PRKAA2 (0.68) | PRKAA2ADORA2ARXRATNKSTNKS2 | |
| SCHEMBL27512912 | 0.68 | PRKAA2 (0.68) | PRKAA2ADORA2ARXRATNKSTNKS2 | |
| SCHEMBL27950491 | 0.68 | PRKAA2 (0.68) | PRKAA2ADORA2ARXRATNKSTNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160185734-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 5-HYDROXY-3-KETOESTER | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-06-30 | — | — | US | claimed |
| CN-103508947-A | Preparation method of pitavastatin calcium | WEIHAI WEITAI PHARMACEUTICAL TECHNOLOGY DEV CO LTD | 2014-01-15 | — | — | CN | claimed |
| US-5369109-A | Optically active esters of 7-substituted 3,5-difunctionalized 6-heptenoic acids | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1994-11-29 | — | — | US | claimed |
| EP-0475627-B1 | Optically active esters of 7-substituted 3,5-difunctionalized 6-heptenoic acids | SAGAMI CHEM RES (JP) | 1994-10-19 | — | — | EP | claimed |
| US-5276154-A | Optically active esters of 7-substituted 3,5-difunctionalized 6-heptenoic acids | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1994-01-04 | — | — | US | claimed |
| EP-0475627-A1 | Optically active esters of 7-substituted 3,5-difunctionalized 6-heptenoic acids | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1992-03-18 | — | — | EP | claimed |
| US-9701642-B2 | Method for producing optically active 5-hydroxy-3-ketoester | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-07-11 | — | — | US | disclosed |
| EP-3178812-A1 | NOVEL POLYMORPHS OF PITAVASTATIN CALCIUM | Hetero Research Foundation (IN) | 2017-06-14 | — | — | EP | disclosed |
| US-20160185734-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 5-HYDROXY-3-KETOESTER | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-06-30 | — | — | US | disclosed |
| EP-2598484-B1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS (SI) | 2016-06-29 | — | — | EP | disclosed |
| US-9085538-B2 | Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof | LEK PHARMACEUTICALS D.D. (SI) | 2015-07-21 | — | — | US | disclosed |
| US-20140051854-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2014-02-20 | — | — | US | disclosed |
| CN-103508947-A | Preparation method of pitavastatin calcium | WEIHAI WEITAI PHARMACEUTICAL TECHNOLOGY DEV CO LTD | 2014-01-15 | — | — | CN | disclosed |
| EP-0641762-B1 | Process for preparation of 5-hydroxy-3-ketoester derivative and optically active substance thereof | UBE INDUSTRIES (JP) | 1997-05-28 | — | — | EP | disclosed |
| US-5457225-A | Process for preparation of 5-hydroxy-3-ketoester derivative and optically active substance thereof | UBE INDUSTRIES LTD. (JP) | 1995-10-10 | — | — | US | disclosed |
| EP-0641762-A1 | Process for preparation of 5-hydroxy-3-ketoester derivative and optically active substance thereof | UBE INDUSTRIES, LTD. (JP) | 1995-03-08 | — | — | EP | disclosed |
| US-5369109-A | Optically active esters of 7-substituted 3,5-difunctionalized 6-heptenoic acids | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1994-11-29 | — | — | US | disclosed |
| EP-0475627-B1 | Optically active esters of 7-substituted 3,5-difunctionalized 6-heptenoic acids | SAGAMI CHEM RES (JP) | 1994-10-19 | — | — | EP | disclosed |
| US-5276154-A | Optically active esters of 7-substituted 3,5-difunctionalized 6-heptenoic acids | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1994-01-04 | — | — | US | disclosed |
| EP-0475627-A1 | Optically active esters of 7-substituted 3,5-difunctionalized 6-heptenoic acids | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1992-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185734-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 5-HYDROXY-3-KETOESTER | CYP51A1, HSD3B1, CYP3A5 | PRKAA2 966/4885ADORA2A 4321/4885RXRA 4113/4885 |
| US-20140051854-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | HMGCR, PCSK9, FAH | PRKAA2 317/4885ADORA2A 3765/4885RXRA 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.